|
Re: Take Home Points: not ready for use in patients
|
5
|
Resverlogix Corp.
|
Nov 16, 2019 04:22PM
|
|
Re: BOM 2 Trial
|
5
|
Resverlogix Corp.
|
Jun 10, 2020 12:12PM
|
|
Re: eGFR and Cognition?
|
5
|
Resverlogix Corp.
|
Nov 22, 2019 11:43PM
|
|
Re: A few thoughts
|
5
|
Resverlogix Corp.
|
Nov 16, 2019 06:40PM
|
|
Re: Breakthrough Therapy Question
|
5
|
Resverlogix Corp.
|
Jan 06, 2020 03:00PM
|
|
Re: Shenzhen Hepalink-Warrants Expiration
|
5
|
Resverlogix Corp.
|
Feb 04, 2022 06:08PM
|
|
Re: Resverlogix Clinical Candidate Apabetalone Featured as a Potential COVID-19 Treatment in Recent Publication
|
5
|
Resverlogix Corp.
|
Mar 24, 2020 04:33PM
|
|
RVX-297 vs RVX-208 for autoimmune indications
|
5
|
Resverlogix Corp.
|
Jan 08, 2019 12:18AM
|
|
Re: New Alkaline Phosphate publication from Dr. Kalantar-Zadeh
|
5
|
Resverlogix Corp.
|
Nov 17, 2019 01:01PM
|
|
Re: The waiting game.....
|
5
|
Resverlogix Corp.
|
Feb 12, 2019 06:39PM
|
|
Re: I have a growing concern....
|
5
|
Resverlogix Corp.
|
Feb 28, 2020 12:22PM
|
|
Re: Sedar filings - Loan balance
|
5
|
Resverlogix Corp.
|
Jul 29, 2019 10:20PM
|
|
Re: Another article
|
5
|
Resverlogix Corp.
|
Nov 20, 2019 01:35PM
|
|
Re: balancing success and failure
|
5
|
Resverlogix Corp.
|
Nov 20, 2019 01:59PM
|
|
Re: Epigenetics and Coronavirus
|
5
|
Resverlogix Corp.
|
Mar 23, 2020 04:22PM
|
|
Re: Summary of Proposed BETonMACE2 design and timelines
|
5
|
Resverlogix Corp.
|
Feb 05, 2021 06:16PM
|
|
Re: Off-label drug use in Canada and the USA
|
5
|
Resverlogix Corp.
|
Feb 05, 2021 06:51PM
|
|
Re: No mention of efficacy again...
|
5
|
Resverlogix Corp.
|
Mar 27, 2019 01:44PM
|
|
Re: Congestive heart failure
|
5
|
Resverlogix Corp.
|
Nov 25, 2019 04:21PM
|
|
Righting the (underpowered) vessel
|
6
|
Resverlogix Corp.
|
Oct 31, 2019 04:51PM
|
